Previous 10 | Next 10 |
2024-02-23 07:54:24 ET DENVER, Colo., Feb 23, 2024 (www.247marketnews.com)- Clearmind Medicine Inc. (NASDAQ: CMND ) stated, this morning, that it received approval from the Ministry of Health of Israel to commence its phase I/IIa clinical trial for alcohol use disorder (AUD) patients us...
For the first time, patients with alcohol use disorder will receive the company's unique and proprietary psychedelic - MEAI Vancouver, Canada, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech co...
2024-02-21 08:34:43 ET Losers: Pop Culture Group Co Ltd ( CPOP ) -33% . Shineco ( SISI ) -27% . Palo Alto Networks PANW -24% after Q2 earnings release . Biofrontera ( BFRI ) -23% . Amplitude AMPL -22% after Q4 earnings release . ...
2024-02-20 10:51:37 ET More on SciSparc Ltd. SciSparc announces $20M standby equity purchase agreement SciSparc stock jumps 25% amid MitoCare X Bio investment Financial information for SciSparc Ltd. Read the full article on Seeking Alpha For further d...
2024-02-20 10:00:11 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Healthcare dealmakers see inc...
2024-02-20 09:32:32 ET DENVER, Colo., Feb 20, 2024 (www.247marketnews.com)- Clearmind Medicine Inc. (NASDAQ: CMND ) jointly announced, this morning, with SciSparc Ltd. (NASDAQ: SPRC ), that Clearmind filed three patent applications, under the international Patent Cooperation Treaty,...
Vancouver, Canada, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems,...
TEL AVIV, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part o...
2024-02-12 12:13:32 ET More on ATAI, COMPASS Pathways, etc. Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts De-Risking Psychedelics: Compass Pathways, Cybin And Atai ...
2024-02-05 08:31:42 ET Chenghe Acquisition ( CHEA ) +153% . 4D Molecular Therapeutics ( FDMT ) +54% . BioRestorative Therapies ( BRTX ) +26% Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease. ...
News, Short Squeeze, Breakout and More Instantly...
Vancouver, Canada, July 19, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated healt...
A look at the top 10 most actives in the United States Yoshitsu Co. Ltd (TKLF) rose 103.4% to $0.623 on volume of 309,019,720 shares Maxeon Solar Technologies Ltd. (MAXN) rose 11.2% to $0.2524 on volume of 226,231,487 shares NVIDIA Corporation (NVDA) fell 1.6% to $126.36 on volume of 208,...
Vancouver, Canada, July 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated healt...